Compare Abercrombie & Fitch Co. (ANF) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abercrombie & Fitch Co. vs Merck & Co., Inc. — how do they compare? Abercrombie & Fitch Co. trades at $92.43 (market cap $4.14B), while Merck & Co., Inc. trades at $123.99 (market cap $305.12B). The key difference: Merck & Co., Inc. is far larger — about 73.7× Abercrombie & Fitch Co.'s market cap, and Merck & Co., Inc. pays a 2.75% dividend while Abercrombie & Fitch Co. pays none. Which is the better fit depends on your goals.
| ANF | MRK | |
|---|---|---|
Market Cap | $4.14B | $305.12B |
Sector | Consumer Cyclical | Health |
52-Week High | $129.85 | $129.52 |
52-Week Low | $65.61 | $77.60 |
Enterprise Value | $4.81B | $348.54B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abercrombie & Fitch (ANF) trades at $93.07, up 4.29% with strong fundamental metrics including a P/E of 9 and net income margin of 9.34%. The stock shows consistent earnings beats in recent quarters and maintains robust profitability with ROE at 39.04%. Technical indicators are neutral overall, with bullish moving averages and key resistance at $94. Recent expansion initiatives include APAC growth opportunities and partnerships with Target for back-to-college merchandise.
ANF presents a compelling value opportunity with attractive valuation multiples and strong operational performance. Upside potential exists to the $107.71 consensus price target, though risks include moderating sales growth and international market volatility. The company's disciplined expansion and brand revitalization support long-term growth prospects.
Merck (MRK) trades at $123.54, down 1.22% over the past day, with a bullish technical signal from moving averages and a consensus analyst price target of $135.14. The company reported strong earnings beats in recent quarters, including Q1 2026, and maintains robust profitability with a net income margin of 13.59%. Recent developments include the acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a solid financial position with $13.69 billion in cash.
The outlook for MRK is positive, driven by earnings momentum, strategic acquisitions, and analyst optimism, though risks include rising debt levels and competitive pressures in the pharmaceutical sector. Investment opportunities lie in its high-profit margins and growth initiatives, while investors should monitor execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abercrombie & Fitch Co.
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
